Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY 10021, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY 10021, USA.
Curr Opin Pharmacol. 2020 Aug;53:8-17. doi: 10.1016/j.coph.2020.03.002. Epub 2020 Jun 20.
Osteoclasts are bone-resorbing cells that play an essential role in the remodeling of bone under physiological conditions and numerous pathological conditions, such as osteoporosis, bone metastasis, and inflammatory bone erosion. Nuclear receptors are crucial to various physiological processes, including metabolism, development and inflammation, and function as transcription factors to activate target genes. Synthetic ligands of nuclear receptors are also available for the treatment of metabolic and inflammatory diseases. However, dysregulated bone phenotypes have been documented in patients who take synthetic nuclear receptor ligands as a therapy. Therefore, the effect of nuclear receptors on bone cells has become an important area of exploration; additionally, the molecular mechanisms underlying the action of nuclear receptors in osteoclasts have not been completely understood. Here, we cover the recent progress in our understanding of the roles of nuclear receptors in osteoclasts.
破骨细胞是一种骨吸收细胞,在生理条件下和许多病理条件下,如骨质疏松症、骨转移和炎症性骨侵蚀,都发挥着至关重要的作用。核受体对包括代谢、发育和炎症在内的各种生理过程至关重要,它们作为转录因子激活靶基因。核受体的合成配体也可用于治疗代谢和炎症性疾病。然而,接受合成核受体配体治疗的患者出现了骨表型失调的情况。因此,核受体对骨细胞的影响已成为一个重要的探索领域;此外,核受体在破骨细胞中作用的分子机制尚未完全了解。在这里,我们综述了近年来我们对核受体在破骨细胞中作用的理解的最新进展。